背景:非小细胞肺癌(NSCLC)的发病率很高。大多数非小细胞肺癌在最初诊断时已经发生了多个转移,5年生存率较低。目前,综合治疗,包括全身化疗,靶向治疗,抗血管生成治疗,和免疫疗法,延长晚期NSCLC患者的生存期。在这里,我们报道了1例长期生存的非小细胞肺癌.
方法:2011年7月,一名61岁女性主诉干咳和呼吸急促,到我院就诊。影像学检查显示左上肺肿块伴肝脏多发转移,肾上腺,还有骨头.
方法:诊断为IVB期(cT2aN3M1c)肺腺癌,淋巴结多发转移,肝脏,肾上腺,还有骨头.
结果:患者接受全身化疗和表皮生长因子受体酪氨酸激酶抑制剂靶向治疗,并存活了9年多。
结论:患者受益于维持化疗和表皮生长因子受体酪氨酸激酶抑制剂治疗,并获得长期生存。
BACKGROUND: The incidence of nonsmall cell lung cancer (NSCLC) is high. Most nonsmall cell lung cancers have undergone multiple metastases at the time of initial diagnosis, and the 5 year survival rate is low. At present, comprehensive treatments, including systemic chemotherapy, targeted therapy, antiangiogenic therapy, and immunotherapy, prolong the survival of patients with advanced NSCLC. Herein, we report a
case of NSCLC with long-term survival.
METHODS: A 61-year-old woman complained of dry cough and shortness of breath and visited our hospital in July 2011. Imaging examination revealed a left upper lung mass with multiple metastases to the liver, adrenal gland, and bone.
METHODS: Stage IVB (cT2aN3M1c) lung adenocarcinoma was diagnosed, with multiple metastases of the lymph nodes, liver, adrenal gland, and bone.
RESULTS: The patient received systemic chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor-targeted therapy, and has survived for more than 9 years.
CONCLUSIONS: The patient benefited from maintenance chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor treatment and achieved long-term survival.